Additional file 1: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

  • Narendra Bharathy (Contributor)
  • Noah Berlow (Creator)
  • Eric Wang (Creator)
  • Jinu Abraham (Contributor)
  • Teagan P. Settelmeyer (Creator)
  • Jody E. Hooper (Creator)
  • Matthew N. Svalina (Creator)
  • Zia Bajwa (Creator)
  • Martin W. Goros (Creator)
  • Brian S. Hernandez (Creator)
  • Johannes E. Wolff (Creator)
  • Ranadip Pal (Contributor)
  • Angela M. Davies (Creator)
  • Arya Ashok (Contributor)
  • Darnell Bushby (Creator)
  • Maria Mancini (Creator)
  • Christopher Noakes (Creator)
  • Neal C. Goodwin (Creator)
  • Peter Ordentlich (Creator)
  • James Keck (Creator)
  • Douglas S. Hawkins (Creator)
  • Erin R. Rudzinski (Creator)
  • Atiya Mansoor (Contributor)
  • Theodore J. Perkins (Creator)
  • Christopher R. Vakoc (Creator)
  • Joel E Michalek (Creator)
  • Charles Keller (Creator)



Figure S1. Phosphohistone H3 (pHH3) expression and rhabdomyoblast count in VCR and ENT + VCR-treated eRMS. (a) pHH3 expression of eRMS mouse tumor (animal id: 67833) after treatment with single agent VCR. Scale Bar: 50 μM. (b) pHH3 expression of eRMS mouse tumor (animal id: 67822) after treatment with both ENT and VCR. Scale bar: 50 μM (c) Histological scoring of various mouse eRMS after four different types of treatment; DMSO, VCR, ENT, or a combination of ENT and VCR (ENT + VCR). Counted all fields 500 to 3000 cells under low and higher magnification on each slide. This count excluded endothelial cells and inflammatory cells. * denotes not determined while ** denotes myoglobin was immunohistochemically positive. (TIF 2381 kb)
Datos disponibles2019

Citar esto